Financial Data and Key Metrics Changes - In 2025, WuXi AppTec achieved total revenue of RMB 45.46 billion, with revenue from continuing operations growing 21.4% year-over-year to RMB 43.42 billion [6] - Adjusted non-IFRS net profit grew 41.3% year-over-year to RMB 14.96 billion, with a non-IFRS net profit margin improving 5.9 percentage points to 32.9% [6][21] - The adjusted non-IFRS gross profit reached RMB 21.89 billion, with a gross profit margin expanding to 48.2%, up 6.6 percentage points year-over-year [20] Business Line Data and Key Metrics Changes - WuXi Chemistry revenue grew 25.5% year-over-year to RMB 36.47 billion, with an adjusted non-IFRS gross profit margin of 52.3% [11] - Small molecule D&M business revenue increased 11.4% year-over-year to RMB 19.92 billion [12] - TIDES revenue nearly doubled, growing 96% year-over-year to RMB 11.37 billion [15] Market Data and Key Metrics Changes - Revenue from the U.S. market grew 34.3% year-over-year, while Japan, Korea, and other regions grew 4.1% [8] - Europe and China experienced declines mainly due to fluctuations in project delivery timing [8] Company Strategy and Development Direction - The company remains focused on enhancing its integrated CRDMO core business and improving operational efficiency to meet customer demand [23] - WuXi AppTec aims to sustain rapid business growth, expecting total revenue to reach RMB 51.3 billion - RMB 53 billion in 2026, with continuing operations revenue growing 18%-22% year-over-year [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic challenges, including currency exchange impacts and geopolitical uncertainties [30][31] - The company is committed to maintaining a stable and resilient adjusted non-IFRS net profit margin in 2026 [24] Other Important Information - WuXi AppTec achieved MSCI AAA and CDP Climate Change A ratings in 2025, reflecting its commitment to sustainability [9] - The board proposed a cash dividend distribution plan totaling a record RMB 5.7 billion in 2026, maintaining a 30% annual cash dividend payout ratio [25] Q&A Session All Questions and Answers Question: How does management think about the impact of currency exchange? - Management acknowledged the FX movement and expressed confidence in their execution capabilities despite macroeconomic volatility [30] Question: How would you think about the impact of geopolitics and oil prices on your margins going forward? - Management noted that while there are potential risks to raw material costs, they have not seen direct impacts on operations and will monitor the situation closely [31] Question: What would be the next key modalities that could potentially be the new focus? - Management indicated that while peptide demand is high, they are also seeing growth in oligonucleotides, which could become a significant focus [32] Question: Have you sensed any change in client outsourcing strategy in the past six to 12 months? - Management stated that they are committed to improving capabilities and investing in capacities to meet customer needs, regardless of internal manufacturing trends in the pharmaceutical industry [35] Question: What is WuXi AppTec's positioning in oral small molecule GLP-1 CDMO business? - Management reported double-digit growth in the small molecule sector, with contributions from GLP-1 small molecules [46] Question: How do you see sustainability of TIDES business growth? - Management expressed confidence in sustained growth due to high demand for their largest products and a robust pipeline [54] Question: Can you give us some color on the general timeline that it takes for a new facility to be built? - Management stated that in China, a new facility can become fully operational in less than 12 months [57] Question: How is the current Middle East situation impacting the company's investment view in Saudi Arabia? - Management confirmed that their long-term strategy remains unchanged and they continue to engage with stakeholders in Saudi Arabia [60] Question: What is the company's view on relations between the U.S. and China? - Management expressed confidence that WuXi AppTec will not be included in the 1260H list and emphasized their transparent corporate governance [70]

Group 1 - Core viewpoint: WuXi AppTec is a leading integrated CRDMO provider, delivering efficient global services for the pharmaceutical and life sciences industry through continuous internal and external development [2][13] - The company has a highly experienced management team with a global perspective and is implementing an H-share incentive trust plan to attract and motivate key talent [2][13] - The CRDMO integration is expected to see a slight revenue decline in 2024, but the performance in the first half of 2025 is anticipated to be strong [2][13] Group 2 - The CXO industry is experiencing robust growth due to the long development times, high costs, and low success rates of drug development, leading to a trend of specialization in the pharmaceutical R&D service sector [3][14] - The rapid release of demand in China's pharmaceutical market, along with the increasing trend of refined specialization and the promotion of hierarchical diagnosis and treatment, is driving the prosperity of the CRO industry [3][14] - Pharmaceutical companies' demands for cost control and efficiency improvements are pushing CMO companies to upgrade to CDMO enterprises, resulting in steady growth in the global CDMO market, particularly in China [3][14] Group 3 - WuXi Chemistry offers integrated services with strong capital requirements and high customer stickiness, creating high barriers for CRDMO one-stop services [4][15] - The R&D business has a strong research capability, continuously attracting high-quality molecules, with 621 new molecules added to the D&M pipeline from Q1 to Q3 of 2025, including 250 molecules transitioning from R to D [4][15] - The D&M business is steadily growing in areas such as API services, formulation services, analytical services, and global regulatory affairs support, with a total of 3,430 small molecule D&M pipeline projects expected by the end of September 2025 [4][15] Group 4 - WuXi Testing provides testing solutions, although revenue has fluctuated in recent years [5][16] - The WIND platform offers integrated laboratory analysis and testing services, helping clients shorten drug development timelines while continuously enhancing capacity and global business layout [5][16] - The company has divested its clinical CRO and SMO services, focusing on core business areas, which has been impacted by market pricing factors leading to revenue declines in Q1 to Q3 of 2025 [5][16] Group 5 - WuXi Biology offers comprehensive biological services and solutions, covering all stages of drug discovery and major disease areas, while continuously building capabilities related to new molecular types [6][17] - The company is strengthening its capabilities in drug discovery hotspots and proactively expanding overseas business to efficiently drive the CRDMO business model [6][17] Group 6 - Profit forecast: Under a neutral scenario, the company expects net profit attributable to shareholders to be 15.86 billion, 15.22 billion, and 17.63 billion yuan for 2025-2027, with EPS of 5.32, 5.10, and 5.91 yuan per share, respectively [7][18] - The corresponding PE for 2025 is projected to be 17.44 times, with an initial coverage rating of "Accumulate" [7][18]

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec, with a target price of 137.75 CNY, based on a 29x PE for 2026 [3][5]. Core Insights - WuXi AppTec's revenue for Q3 2025 reached 12.06 billion CNY, reflecting a 15.3% year-on-year increase, with a net profit of 3.52 billion CNY, up 53.3% [10]. - The company has adjusted its revenue guidance for its continuing operations from 42.5-43.5 billion CNY to 43.5-44 billion CNY, indicating a growth rate adjustment from 13-17% to 17-18% [10]. - The company is focusing on its CRDMO business by divesting its clinical services, which accounted for a small portion of its revenue [10]. Financial Performance Summary - For 2025, the forecasted revenue is 44.76 billion CNY, with a projected net profit of 16.35 billion CNY, representing a 73% increase compared to the previous year [3][10]. - The gross margin is expected to improve to 45.6% in 2025, with a net margin of 36.5% [3][10]. - The company's cash and cash equivalents are projected to increase significantly, reaching 34.01 billion CNY by 2025 [13]. Segment Performance - WuXi Chemistry reported a revenue of 25.98 billion CNY for the first three quarters of 2025, a 29.3% increase, with significant growth in TIDES revenue [10]. - The U.S. market contributed 22.15 billion CNY in revenue, marking a 31.9% increase, while European revenue grew by 13.5% [10]. Valuation Metrics - The report provides a comparison of WuXi AppTec's valuation metrics with peers, indicating a PE ratio of 17.2 for 2026, which is competitive within the industry [11]. - The report highlights a projected net asset return (ROE) of 24.1% for 2025, reflecting strong profitability [13]. Market Context - The report notes that the pharmaceutical R&D services market is experiencing high demand, which is expected to continue driving WuXi AppTec's growth [10]. - The company is well-positioned to capitalize on the increasing trend of outsourcing in the pharmaceutical industry [10].

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec, with a target price of 137.75 CNY, reflecting a 29x PE for 2026 [3][5]. Core Insights - WuXi AppTec's revenue for Q3 2025 reached 12.06 billion CNY, representing a 15.3% year-on-year increase, with a net profit of 3.52 billion CNY, up 53.3% [10]. - The company has adjusted its revenue guidance for continuous operations from 42.5-43.5 billion CNY to 43.5-44 billion CNY, indicating a growth rate increase from 13-17% to 17-18% [10]. - The company is focusing on its CRDMO business by divesting its clinical services, which accounted for only 3.5% of revenue in the first three quarters [10]. Financial Performance Summary - Revenue projections for 2025-2027 have been revised to 44.76 billion CNY, 50.39 billion CNY, and 57.07 billion CNY, respectively, with corresponding net profits of 16.35 billion CNY, 14.19 billion CNY, and 16.58 billion CNY [3][4]. - The gross margin is expected to improve to 45.6% in 2025, with net profit margins projected at 36.5% [4][10]. - The company reported a significant increase in backlogged orders, reaching 59.88 billion CNY, up 41.2% year-on-year, indicating strong future revenue potential [10].

Investment Rating - The investment rating for WuXi AppTec is maintained as "Buy" for both A and H shares [6][7]. Core Views - The company reported a revenue of 39.24 billion RMB for 2024, a decrease of 2.7% year-on-year, but a growth of 5.2% year-on-year when excluding COVID-19 impacts, which aligns with expectations [1]. - The net profit attributable to shareholders for 2024 was 9.45 billion RMB, down 1.6% year-on-year, while the adjusted non-IFRS net profit was 10.58 billion RMB, a decrease of 2.5% year-on-year [1]. - The company has seen a significant increase in its order backlog, with expectations for accelerated growth in 2025-2026, leading to a positive outlook [1][2]. Summary by Sections Financial Performance - In Q4 2024, revenue increased by 6.9% year-on-year, and net profit attributable to shareholders surged by 90.6% year-on-year, driven by improved operational efficiency and favorable exchange rate fluctuations [1]. - The company’s gross margin improved to 43.5% in Q4 2024 from 40.9% in Q4 2023 [1]. Order Backlog and Growth Prospects - As of the end of 2024, the order backlog reached 49.31 billion RMB, reflecting a year-on-year growth of 47.0% [2]. - The TIDES segment showed remarkable growth, with order backlog increasing by 104% year-on-year [2]. Segment Performance - WuXi Chemistry reported a revenue of 29.05 billion RMB in 2024, a slight decrease of 0.4% year-on-year, but a growth of 11.2% year-on-year when excluding COVID-19 impacts [3]. - The CDMO segment generated 17.87 billion RMB, with a year-on-year growth of 6.4% when excluding COVID-19 impacts [3]. Profitability Forecast - The forecast for net profit attributable to shareholders for 2025-2027 is 11.79 billion RMB, 13.56 billion RMB, and 16.74 billion RMB, representing year-on-year growth rates of 24.8%, 14.95%, and 23.5% respectively [5]. - The company’s target prices are set at 89.42 RMB for A shares and 100.99 HKD for H shares, based on a sum-of-the-parts valuation [5][6]. Valuation - The company is valued at 258.24 billion RMB for A shares and 291.66 billion HKD for H shares, reflecting adjustments due to changes in the DDSU segment [11].